Jennifer Marcello

4.0k total citations · 1 hit paper
34 papers, 3.1k citations indexed

About

Jennifer Marcello is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Jennifer Marcello has authored 34 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 13 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Jennifer Marcello's work include Glioma Diagnosis and Treatment (19 papers), Brain Metastases and Treatment (9 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Jennifer Marcello is often cited by papers focused on Glioma Diagnosis and Treatment (19 papers), Brain Metastases and Treatment (9 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Jennifer Marcello collaborates with scholars based in United States, Australia and Sri Lanka. Jennifer Marcello's co-authors include James E. Herndon, Annick Desjardins, James J. Vredenburgh, Henry S. Friedman, David A. Reardon, Allan H. Friedman, John H. Sampson, Sridharan Gururangan, Sith Sathornsumetee and Jeremy N. Rich and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jennifer Marcello

33 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jennifer Marcello

Since Specialization

Citations

This map shows the geographic impact of Jennifer Marcello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Marcello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Marcello more than expected).

Fields of papers citing papers by Jennifer Marcello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Marcello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Marcello. The network helps show where Jennifer Marcello may publish in the future.

Co-authorship network of co-authors of Jennifer Marcello

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Marcello. A scholar is included among the top collaborators of Jennifer Marcello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Marcello. Jennifer Marcello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Influence of a Physician and Patient Intervention Program on Dietary Intake 2013 ·Journal of the Academy of Nutrition and Dietetics ·(unknown), William S. Yancy, Kathryn I. Pollak, Rowena J Dolor, Jennifer Marcello, Gregory P. Samsa, Bryan C. Batch, Laura P. Svetkey	27
2	Hazard-Rate Analysis and Patterns of Recurrence in Early Stage Melanoma: Moving towards a Rationally Designed Surveillance Strategy 2013 ·PLoS ONE ·April K.S. Salama, Nicole de Rosa, Randall P. Scheri, Scott K. Pruitt, James E. Herndon, Jennifer Marcello, Douglas S. Tyler, Amy P. Abernethy	36
3	The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost 2012 ·Cancer Investigation ·April K.S. Salama, Nicole de Rosa, Randall P. Scheri, James E. Herndon, Douglas S. Tyler, Jennifer Marcello, Scott K. Pruitt, Amy P. Abernethy	6
4	The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma 2011 ·Clinical Cancer Research ·James J. Vredenburgh, Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, John H. Sampson, Leighann Bailey, Stevie Threatt, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman	112
5	Bevacizumab and daily temozolomide for recurrent glioblastoma 2011 ·Cancer ·Annick Desjardins, David A. Reardon, April Coan, Jennifer Marcello, James E. Herndon, Leighann Bailey, Katherine B. Peters, Henry S. Friedman, James J. Vredenburgh	117
6	Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial 2010 ·The Lancet ·Amy P. Abernethy, Christine F. McDonald, Peter Frith, Katherine Clark, James E. Herndon, Jennifer Marcello, Iven H Young, Janet Bull, Andrew Wilcock, Sara Booth, Jane L. Wheeler, James A. Tulsky, Alan Crockett, David C. Currow	281
7	Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme 2010 ·International Journal of Radiation OncologyBiologyPhysics ·James J. Vredenburgh, Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, Leighann Bailey, Stevie Threatt, John H. Sampson, Allan H. Friedman, Henry S. Friedman	66
8	Evaluation of 39 cases of pediatric cutaneous head and neck melanoma 2010 ·Journal of the American Academy of Dermatology ·(unknown), Jennifer Marcello, (unknown), Amy P. Abernethy, Kelly C. Nelson	11
9	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy 2010 ·Journal of Neuro-Oncology ·David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Jeremy N. Rich, Roger E. McLendon, James E. Herndon, Jennifer Marcello, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman	74
10	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma 2010 ·Journal of Neuro-Oncology ·David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, James E. Herndon, Roger E. McLendon, (unknown), Allan H. Friedman, Darell D. Bigner, Henry S. Friedman	101
11	Association between body mass index and mortality in patients with glioblastoma mutliforme 2010 ·Cancer Causes & Control ·Lee W. Jones, Francis Ali‐Osman, Eric Lipp, Jennifer Marcello, Bridget J. McCarthy, Lucie McCoy, Terri Rice, Margaret Wrensch, Dora Il’yasova	26
12	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma 2009 ·Journal of Neuro-Oncology ·David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, J. Norfleet, Roger E. McLendon, John H. Sampson, Henry S. Friedman	181
13	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study 2009 ·British Journal of Cancer ·David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Sith Sathornsumetee, Roger E. McLendon, James E. Herndon, Jennifer Marcello, J. Norfleet, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman	161
14	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas 2008 ·Clinical Cancer Research ·Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John H. Sampson, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh	130
15	Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems 2008 ·BMC Cancer ·S. Yousuf Zafar, Amy P. Abernethy, David H. Abbott, Steven C. Grambow, Jennifer Marcello, James E. Herndon, (unknown), (unknown), Leah L. Zullig, Meenal Patwardhan, Dawn Provenzale	41
16	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme breakdown → 2007 ·Journal of Clinical Oncology ·James J. Vredenburgh, Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John H. Sampson, (unknown), Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman	1049
17	Development of models and detection methods for different forms of cytomegalovirus for the evaluation of viral inactivation agents 2006 ·Transfusion ·(unknown), Jennifer Marcello, Åsa Öhagen, Veronica Gibaja, (unknown), (unknown), John Chapman, (unknown)	12
18	Retinoic Acid Inhibition of Chromatin Remodeling at the Human Immunodeficiency Virus Type 1 Promoter 2004 ·Journal of Biological Chemistry ·(unknown), Timothy M. Hanley, Jennifer Marcello, (unknown), Gregory A. Viglianti	19
19	Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110 2004 ·Vox Sanguinis ·Åsa Öhagen, Veronica Gibaja, (unknown), (unknown), (unknown), Jennifer Marcello, John Chapman, (unknown)	16
20	Retinoid-Dependent Restriction of Human Immunodeficiency Virus Type 1 Replication in Monocytes/Macrophages 2004 ·Journal of Virology ·Timothy M. Hanley, (unknown), Aletta C. Schnitzler, Jennifer Marcello, Gregory A. Viglianti	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact